Current Approaches to Assessing the Safety and Efficacy of Lamotrigine in Children and Adolescents with Epileptic Syndromes Associated with Focal Seizures

Scientific relevance. Epileptic syndromes associated with focal seizures often develop in children and adolescents and may be accompanied by cognitive impairment, mental disorders, and endocrine disorders, which require additional medication apart from anti-epileptic medicinal products. Currently, the selection of safe and effective therapies for epileptic syndromes, especially in paediatric populations, is a pressing challenge for epileptology.

Aim. This study aimed at a comprehensive assessment of the safety and efficacy of lamotrigine in therapeutic doses for children and adolescents with epileptic syndromes associated with focal seizures.

Materials and methods. A total of 53 patients aged 3 to 18 years with various epileptic syndromes associated with focal seizures were under observation in 2020–2023. During this period, 37 patients (69.8%) received monotherapy with lamotrigine, and 16 patients (30.2%) received combination therapy including lamotrigine and two or more other medicinal products. When evaluating the safety and efficacy of pharmacotherapy in adolescent patients, the authors selectively used the Software for Post-marketing Studies of Anti-epileptic Medicinal Products developed at the Scientific Centre for Expert Evaluation of Medicinal Products.

Results. With lamotrigine, the highest rate of complete clinical remission was observed in patients with focal epilepsy with onset in childhood and adolescence (90.9% of cases). For structural focal epilepsy, 16.7% of patients achieved complete freedom from seizures, and 50% demonstrated a pronounced response to treatment. However, patients with epilepsy due to local structural changes in the neocortex (33.3% of cases) had a prognosis of severe epilepsy. For epileptic encephalopathies with onset in childhood, 66.7% of patients achieved a ≥50% reduction in the frequency of seizures. Seizure reduction improved the quality of life of patients and their parents, especially of those with a long history of unsuccessful treatment attempts. There were no adverse reactions associated with lamotrigine except those listed in the summary of product characteristics. The Software for Post-marketing Studies of Anti-epileptic Medicinal Products provided a means for scoring and plotting the changes in the condition of adolescents without severe cognitive and memory impairment undergoing lamotrigine treatment.

Conclusions. According to the study results, lamotrigine is highly effective and has a favourable safety profile in patients with early-onset epileptic syndromes associated with focal seizures. Moreover, lamotrigine is applicable to the treatment of attention, memory, expressive speech disorders, and aggressive behaviour. Therefore, lamotrigine may be recommended for treating children and adolescents with comorbid epileptic syndromes and cognitive and emotional disorders. Specialised software improves the quality of real-world evidence regarding the safety and efficacy of anti-epileptic medication.

1. Zenkov LR. Neuropathophysiology of epileptic encephalopathies and non-paroxysmal epileptic disorders and principles of their treatment. Neurology, Neuropsychiatry, Psychosomatics. 2010;(2):26–32 (In Russ.). EDN: MUQOED

2. Mukhin КYu. Forward to Jackson! Epilepsy and Paroxysmal Conditions. 2021;13(1S):61–4 (In Russ.). https://doi.org/10.17749/2077-8333/epi.par.con.2021.080

3. Specchio N, Wirrell EC, Scheffer IE, Nabbout R, Riney K, Samia P, et al. International League Against Epilepsy classification and definition of epilepsy syndromes with onset in childhood: position paper by the ILAE task force on nosology and definitions. Epilepsia. 2022;63(6):1398–442. https://doi.org/10.1111/epi.17241

4. Marson A, Burnside G, Appleton R, Smith D, Leach JP, Sills G, et al. The SANAD II study of the effectiveness and cost-effectiveness of levetiracetam, zonisamide, or lamotrigine for newly diagnosed focal epilepsy: an open-label, non-inferiority, multicentre, phase 4, randomised controlled trial. Lancet. 2021;397(10282):1363–74. https://doi.org/10.1016/S0140-6736(21)00247-6

5. Knight R, Wittkowski A, Bromley RL. Neurodevelopmental outcomes in children exposed to newer antiseizure medications: a systematic review. Epilepsia. 2021;62(8):1765–79. https://doi.org/10.1111/epi.16953

6. Kumar R, Garzon J, Yuruk D, Hassett LC, Saliba M, Ozger C, et al. Efficacy and safety of lamotrigine in pediatric mood disorders: a systematic review. Acta Psychiatr Scand. 2023;147(3):248–56. https://doi.org/10.1111/acps.13500

7. Arkhipov VV, Mantserov KM. Personalized methodological approaches to the issues of monitoring the effectiveness and safety of pharmacotherapy with antiepileptic drugs based on mobile medicine technologies. Personalized Psychiatry and Neurology. 2023;3(1):22–7 (In Russ.). https://doi.org/10.52667/2712-9179-2023-3-1-22-27

8. Mironov MB, Chebanenko NV, Bychenko VG, Rubleva YuV, Burd SG, Krasilshikova TM. Comorbidity of infantile cerebral palsy and benign epileptiform EEG discharges of childhood in dizygotic twins. Epilepsy and Paroxysmal Conditions. 2018;10(3):52–62 (In Russ.). https://doi.org/10.17749/2077-8333.2018.10.3.052-062

9. Mukhin KYu, Mironov MB, Borovikov KS, Petrukhin AS. Focal epilepsy of childhood with structural brain changes and benign epileptiform discharges in EEG, SFEСS-BEDC (preliminary results). Russian Journal of Child Neurology. 2010;5(1):3–18 (In Russ.). EDN: MTWUVP

10. Mironov MB, Chebanenko NV, Zykov VP, Bychenko VG, Mednaya DM, Krasilshchikova TM, Milovanova OA. Epileptic syndromes associated with focal clonic seizures. S.S. Korsakov Journal of Neurology and Psychiatry. 2023;123(3):41–5 (In Russ.). https://doi.org/10.17116/jnevro202312303141

11. Pylaeva OA, Mukhin KYu. Efficacy and tolerability of Seizar (lamotrigine) in the treatment of epilepsy (experience of Svt. Luka’s Institute of Child Neurology and Epilepsy). Russian Journal of Child Neurology. 2020;15(2):17–41 (In Russ.). https://doi.org/10.17650/2073-8803-2020-15-2-17-41

12. Mukhin KYu, Pylaeva OA, Bobylova MYu, Freydkova NV. Lamotrigine (Sazar) in the treatment of epilepsy: four years of experience in Svt. Luka’s Association of Medical institutions for the Diagnosis, Treatment, and Rehabilitation of Nervous System Diseases and Epilepsy. Russian Journal of Child Neurology. 2022;17(3):8–36 (In Russ.). https://doi.org/10.17650/2073-8803-2022-17-3-8-36

13. Mukhin KYu, Mironov MB, Borovikov KS, Borovikova NYu. Electric clinical semiology and chronologic features of epileptic seizures associated with focal epilepsy in children with structural changes in brain and benign epileptiform patterns on EEG. Epilepsy and Paroxysmal Conditions. 2012;(4):18–25 (In Russ.). EDN: PXKRGN

14. Groszer M. Rare human ATP6V1A variants provide unique insights into V-ATPase functions. Brain. 2022;145(8):2626–28. https://doi.org/10.1093/brain/awac255

15. Guerrini R, Mei D, Kerti-Szigeti K, Pepe S, Koenig MK, Von Allmen G, et al. Phenotypic and genetic spectrum of ATP6V1A encephalopathy: a disorder of lysosomal homeostasis. Brain. 2022;145(8):2687–703. https://doi.org/10.1093/brain/awac145

16. Effectiveness, safety and assessing the results of drug therapy in patients with epilepsy. Epilepsy and Paroxysmal Conditions. 2021;13(3):306–10 (In Russ.). https://doi.org/10.17749/2077-8333/epi.par.con.2021.093